Clinical Trial Update: A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tucatinib with capecitabine and trastuzumab in advanced HER2-positive breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Seagen Inc. | Conditions: HER2 Positive Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-09-28